<?xml version="1.0" encoding="UTF-8"?>
<p id="Par34">The objective of this trial is to assess the safety and feasibility of delivering SABR to patients with polymetastatic cancer (greater than 10 sites of disease) by establishing the MTD of SABR when given at 6â€‰Gy per fraction.</p>
